Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report

Summary Osimertinib is a key drug for cancer patients with EGFR mutations. However, there is little information about its safety in cancer patients who require hemodialysis (HD) for chronic renal failure, despite notable increases in their numbers. Herein, we examined osimertinib safety in such a pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2020-08, Vol.38 (4), p.1192-1195
Hauptverfasser:	Matsunashi, Atsushi, Fujimoto, Daichi, Hosoya, Kazutaka, Irie, Kei, Fukushima, Shoji, Tomii, Keisuke
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Aged Aniline Compounds Antineoplastic Agents - blood Antineoplastic Agents - pharmacokinetics Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - therapy Case reports Diabetes mellitus Diabetic nephropathy Dialysis Epidermal growth factor receptors ErbB Receptors - genetics Hemodialysis Humans Lung cancer Lung Neoplasms - blood Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - therapy Male Medicine Medicine & Public Health Mutation Nephropathy Non-small cell lung carcinoma Oncology Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Protein Kinase Inhibitors - blood Protein Kinase Inhibitors - pharmacokinetics Radiation therapy Recurrence Renal cell carcinoma Renal Dialysis Renal failure Renal Insufficiency - blood Renal Insufficiency - genetics Renal Insufficiency - metabolism Renal Insufficiency - therapy Safety Short Report Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!